Top

International Journal of Clinical Oncology

Published in:

01-12-2017 | Original Article

A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer

Authors: Jianda Huang, Tongjie Gu, Jun Ying

Published in: International Journal of Clinical Oncology | Issue 6/2017

Abstract

Background

A number of studies have investigated the clinical significance of bone turnover markers (BTMs) for the diagnosis of bone metastasis (BM) in lung cancer; however, they led to contradictory results. The aim of this meta-analysis was to investigate whether BTMs differ between lung cancer patients with and without BM.

Methods

Articles were identified by searching Medline, Embase, Web of Science and Scopus. The studies that were identified were pooled and the weighted mean difference (WMD) and its corresponding 95% confidence interval (CI) were calculated. Subgroup analyses and publication bias detection were also conducted.

Results

A final analysis of 1720 subjects (707 patients with BM and 1013 patients without BM) was performed from 16 cohort studies. From the pooled data in the meta-analysis, the total alkaline phosphatase (TALP) (104.35 U/l [95% CI 33.36−175.34]), bone-specific ALP (BALP) (13.24 μg/l [95% CI 8.50−17.98] or 6.84 U/l [95% CI 2.98−10.70]), C-terminal cross-linked telopeptide of type I collagen (ICTP) (5.07 μg/l [95% CI 3.58−6.56]) and N-terminal cross-linked telopeptide of type I collagen (NTX) (5.08 nM bone collagen equivalent/l [95% CI 2.82−7.33]) were significantly lower among BM patients than non-BM patients. Subgroup analyses detected that the serum level of tartrate-resistant acid phosphatase isoform 5b was significantly reduced in Caucasian patients with BM (−0.64 U/l [95% CI −1.02 to −0.25]), while increased in Asian patients with BM (2.69 U/l [95% CI 0.08−5.31]), compared to patients without BM.

Conclusions

The present meta-analysis suggested that serum measurement of TALP, BALP, ICTP and NTX might be helpful in detecting BM in lung cancer.

Available only for authorised users

Fisseler-Eckhoff A (2010) Prognostic factors in histopathology of lung cancer. Front Radiat Ther Oncol 42:1–14PubMed

Yin JJ, Pollock CB, Kelly K (2005) Mechanisms of cancer metastasis to the bone. Cell Res 15:57–62CrossRefPubMed

Suva LJ, Washam C, Nicholas RW et al (2011) Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol 7:208–218CrossRefPubMedPubMedCentral

Mundy GR (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2:584–593CrossRefPubMed

Lewis P, Griffin S, Marsden P et al (1994) Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265–1266CrossRefPubMed

Ebert W, Muley T, Herb KP et al (2004) Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 24:3193–3201PubMed

Gomez LN, Escalona S, Bandres B et al (2014) (18)F-fluorodeoxyglucose positron emission tomography/computed tomography accuracy in the staging of non-small cell lung cancer: review and cost-effectiveness. Radiol Res Pract 2014:135934

Biver E (2012) Use of bone turnover markers in clinical practice. Curr Opin Endocrinol Diabetes Obes 19:468–473CrossRefPubMed

Pecoraro V, Roli L, Germagnoli L et al (2015) The prognostic role of bone turnover markers in multiple myeloma patients: the impact of their assay. A systematic review and meta-analysis. Crit Rev Oncol Hematol 96:54–66CrossRefPubMed

10.

Ferreira A, Alho I, Casimiro S et al (2015) Bone remodeling markers and bone metastases: from cancer research to clinical implications. Bonekey Rep 4:668CrossRefPubMedPubMedCentral

11.

Lumachi F, Santeufemia DA, Del CA et al (2013) Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer. Anticancer Res 33:2593–2596PubMed

12.

Tang C, Liu Y, Qin H et al (2013) Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients. Clin Chim Acta 426:102–107CrossRefPubMed

13.

Bayrak SB, Ceylan E, Serter M et al (2012) The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer. Int J Clin Oncol 17:112–118CrossRefPubMed

14.

Tamiya M, Suzuki H, Kobayashi M et al (2012) Usefulness of the serum cross-linked N-telopeptide of type I collagen as a marker of bone metastasis from lung cancer. Med Oncol 29:215–218CrossRefPubMed

15.

Lumachi F, Marino F, Fanti G et al (2011) Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results. Anticancer Res 31:3879–3881PubMed

16.

Yao NS, Wu YY, Janckila AJ et al (2011) Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients. Clin Chim Acta 412:181–185CrossRefPubMed

17.

Terpos E, Kiagia M, Karapanagiotou EM et al (2009) The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 29:1651–1657PubMed

18.

Min JW, Um SW, Yim JJ et al (2009) The role of whole-body FDG PET/CT, Tc 99 m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer. J Korean Med Sci 24:275–280CrossRefPubMedPubMedCentral

19.

Dane F, Turk HM, Sevinc A et al (2008) Markers of bone turnover in patients with lung cancer. J Natl Med Assoc 100:425–428CrossRefPubMed

20.

Chung JH, Park MS, Kim YS et al (2005) Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J 46:388–393CrossRefPubMedPubMedCentral

21.

Yokoyama T, Yamamoto M, Shima K et al (2005) Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen for diagnosis of bone metastases in patients with primary lung cancer. Respirology 10:300–304CrossRefPubMed

22.

Alatas F, Alatas O, Metintas M et al (2002) Usefulness of bone markers for detection of bone metastases in lung cancer patients. Clin Biochem 35:293–296CrossRefPubMed

23.

Izumi M, Nakanishi Y, Takayama K et al (2001) Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer 91:1487–1493CrossRefPubMed

24.

Horiguchi T, Tachikawa S, Kondo R et al (2000) Usefulness of serum carboxy-terminal telopeptide of type I collagen (ICTP) as a marker of bone metastasis from lung cancer. Jpn J Clin Oncol 30:174–179CrossRefPubMed

25.

Aruga A, Koizumi M, Hotta R et al (1997) Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 76:760–764CrossRefPubMedPubMedCentral

26.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6:e1000100CrossRefPubMedPubMedCentral

27.

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605CrossRefPubMed

28.

Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560CrossRefPubMedPubMedCentral

29.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

30.

Coleman R, Brown J, Terpos E et al (2008) Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 34:629–639CrossRefPubMedPubMedCentral

31.

Lipton A, Costa L, Ali SM et al (2001) Bone markers in the management of metastatic bone disease. Cancer Treat Rev 27:181–185CrossRefPubMed

32.

Brown JE, Cook RJ, Major P et al (2005) Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 97:59–69CrossRefPubMed

33.

Ali SM, Demers LM, Leitzel K et al (2004) Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis. Ann Oncol 15:455–459CrossRefPubMed

34.

Kaira R, Murakami H, Kaira K et al (2010) N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases. Int J Clin Oncol 15:484–488CrossRefPubMed

35.

Magnusson P, Larsson L, Magnusson M et al (1999) Isoforms of bone alkaline phosphatase: characterization and origin in human trabecular and cortical bone. J Bone Miner Res 14:1926–1933CrossRefPubMed

36.

Seibel MJ (2005) Clinical use of markers of bone turnover in metastatic bone disease. Nat Clin Pract Oncol 2(504–517):1–533

37.

Janckila AJ, Takahashi K, Sun SZ et al (2001) Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47:74–80PubMed

38.

Wu YY, Janckila AJ, Ku CH et al (2010) Serum tartrate-resistant acid phosphatase 5b activity as a prognostic marker of survival in breast cancer with bone metastasis. BMC Cancer 10:158CrossRefPubMedPubMedCentral

39.

Wada N, Ishii S, Ikeda T et al (1999) Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 19:4515–4521PubMed

40.

Mountzios G, Ramfidis V, Terpos E et al (2011) Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data. Clin Lung Cancer 12:341–349CrossRefPubMed

Title: A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer
Authors: Jianda Huang
Tongjie Gu
Jun Ying
Publication date: 01-12-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 6/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-017-1159-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2017

Association of decreased mean platelet volume with renal cell carcinoma

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer

Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis

List of reviewers 2016–2017

Esophageal stenosis and the Glasgow Prognostic Score as independent factors of poor prognosis for patients with locally advanced unresectable esophageal cancer treated with chemoradiotherapy (exploratory analysis of JCOG0303)

Matched-pair analysis of patients with advanced hypopharyngeal cancer: surgery versus concomitant chemoradiotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer